Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder which results from absence or malfunction of the respiratory burst oxidase normally expressed in neutrophils and other phagocytic leukocytes. Two-thirds of the patients are males hemizygous for mutations in the X-linked gene coding for gp91-phox. As a therapeutic approach towards the Xlinked form of CGD bicistronic retroviral vectors containing the gp91-phox gene and a selectable marker gene were constructed. The ability of these vectors to restore NADPH oxidase activity was tested in a human myeloid leukemic cell line that is defective in superoxide production, as well as in primary CD34
bound 91 kDa glycoprotein referred to as gp91-phox. Since inheritance of gp91-phox deficiency is X-linked, mothers of affected male patients are carriers of normal and dysfunctional cells.
CGD can be cured by bone marrow transplantation. However, BMT in CGD has been associated with unacceptably high rates of morbidity, mortality, and graft failure, except in very selected cases with an HLA-identical donor available. Given the life-threatening character of the syndrome, CGD is a first-choice candidate for somatic gene therapy. In addition, CGD has well-defined molecular genetics, easily accessible target tissues for ex vivo gene therapy (bone marrow or peripheral blood cells), and for a large number of patients there is no safe alternative cure. Furthermore, full reconstitution of the defect is not required for restoring a normal phenotype. Thus, it has been shown in both asymptomatic X-CGD carriers and in a transgene mouse model that superoxide production as low as 5-8% of normal levels is sufficient to maintain a normal phenotype. 7, 8 Since functionally corrected CGD cells will not have a selective advantage over their defective, non-transduced counterparts it is critical for a successful gene therapy approach in X-CGD to achieve high levels of gene transfer into the appropriate target cells. Similarly, an efficient and long-lasting expression of the therapeutic gene in the effector cells is required. Through a systematic analysis of retroviral vectors and transduction conditions we have achieved high and long lasting reconstitution of superoxide generating activity in X-CGD cells.
Materials and methods

Cell lines
The GP+E86 and GP+envAm12 9 packaging cell lines and NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum. The human premyeloid leukemia cell line PLB-985 and the gp91-phox deficient X-CGD PLB-985 cell lines were cultivated as described by Zhen et al. 10 Granulocytic differentiation of PLB-985 cells and derivatives was induced with 0.5% dimethyl formamide (DMF) as described by Kume and Dinauer. 11 
Transduction of X-CGD PLB-985 cells
X-CGD PLB-985 cells were transduced by co-cultivation on irradiated (20 Gy) GP+envAm12 producer cells essentially as described by Kume and Dinauer. 11 After infection, X-CGD cells were incubated for 48 h in RPMI prior to the addition of G418 at a concentration of 1 mg/ml (active substance). Pools of neomycin-resistant cells were finally expanded and used for molecular and functional analysis.
Transduction of CD34
+ cells
Protocol I: CD34 + cells were seeded on irradiated allogeneic bone marrow-derived fibroblasts in IMDM supplemented with 20% FCS (Hyclone, UT, USA), glutamine (1%), ␤-mercaptoethanol (5 × 10 −7 m), IL-3 (20 ng/ml), IL-6 (100 U/ml) and SCF (50 ng/ml) for 20 h, and subsequently transduced with cell-free retrovirus supernatant collected in CD34
+ cell culture media. The retroviral supernatant was complemented with the cytokine cocktail mentioned above before transduction. Virus supernatant was changed every 24 h for 3 consecutive days.
Protocol II: CD34
+ cells were prestimulated at a cell concentration of 1 × 10 5 cells/ml for 20 h in serum-free Xvivo10 medium supplemented with 1% BSA, 2 mm l-glutamine and 1% penicillin-streptomycin in the presence of IL-3 (20 ng/ml), IL-6 (100 U/ml), SCF (50 ng/ml), Flt3-L (100 ng/ml) and anti-TGF ␤1 (100 ng/ml) unless otherwise stated. In all experiments, cytokines were maintained throughout the culture period at the concentrations given above. After pre-stimulation, transduction was performed on 3 consecutive days by replacing half of the cell culture medium with retroviral supernatant, supplemented with the cytokine combination mentioned above and protamine sulfate to a final concentration of 4 g/ml. Cells were centrifugated on 24-well plates at 2500 r.p.m./min and 32°C for 90 min (spinoculation), before incubating at 37°C, 5% CO 2 for an additional period of 2.5 h. Afterwards, half of the medium was replaced by fresh X-vivo10 medium containing cytokine cocktail mentioned above. In selected experiments, plates were coated with the fibronectin-fragment CH-296 (RetroNectin, kindly provided by Takara Shuzo, Shiga, Japan). At day 5, cells were harvested, washed, counted and analyzed for the presence of the CD34 antigen and LNGFR expression by FACS.
Transduction efficiency was estimated by seeding 5000 mononuclear cells in 1.1% methylcellulose supplemented with IMDM, 30% FCS (Hyclone), glutamine (1%), ␤-mercaptoethanol (5 × 10 −7 m), IL-3 (10 ng/ml), G-CSF (10 ng/ml), GM-CSF (10 ng/ml), Epo (2 U/ml) and G-418 (1 mg/ml). Neomycin-resistant colonies were counted after 14 days. For retroviral vectors containing the LNGFR marker gene transduction effciencies were estimated by FACS analysis.
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Results
Construction of retroviral vectors carrying the gp91-phox cDNA
The murine stem cell virus backbone (MSCVneoEB 13 ) was used for the construction of a series of vectors in which expression of the gp91-phox cDNA is controlled either by the MSCV LTR (MSCVgp91/pgk-neo) or by an internal phosphoglycerate kinase (pgk) promoter (MSCVneo/pgkgp91 ( Figure 1) . A further construct contained an internal ribosomal entry site (IRES) derived from polyovirus 14 to enable expression of the neomycin resistance genes from a bicistronic transcript (MSCVgp91/ires-neo). The vectors were transiently transfected into the ecotropic helper packaging cells GP+E86 and cell-free supernatants thereof were used to transduce the amphotropic packaging cells GP+envAm12. 9 Several clones of virus producing cells were isolated for each construct in G418. Virus titers of clonal lines varied between 1-5 × 10 5 cfu/ml. The producers with the highest titer were used to transduce X-CGD PLB-985 cells 10 as described in Materials and methods. Transfectants were selected in G418, expanded and used for further analysis.
Functional reconstitution of NADPH-oxidase activity in X-CGD PLB-985 cells
Pools of neo-resistant X-CGD PLB-985 cells were cultured in the presence of 0.5% dimethyl-formamide to induce granulocytic differentiation. A quantitative cytochrome-c reduction assay was performed to accurately estimate the degree of correction achieved by the different retroviral constructs. 15 As shown in Figure 2 , the respiratory burst oxidase activity was reconstituted to high levels only in cells transduced with MSCVgp91/pgk-neo. The relative maximal velocity of superoxide production in cells transduced with MSCVgp91/pgk-neo was 56% of that observed in wild-type PLB-985 cells, while the cumulative superoxide production approached levels similar to those observed in the PLB-985 cells. 
Gp91-phox expression in transduced cells
The variable reconstitution levels observed with the different vectors may have been simply caused by variations in virus infectivity. To investigate this, genomic DNA from infected cells was cleaved with NheI and hybridized on Southern blots to a neo-specific probe. Since NheI cuts once in the U3 region of the proviral genome, we expected internal fragments of 4.6 kb, 4.8 kb and 4.7 kb for MSCVgp91/pgk-neo, MSCVgp91/ires-neo and MSCVneo/ pgk-gp91, respectively (Figure 3a) . Densitometry analysis of the blots showed essentially equal band intensities, indicating that the cells contained comparable numbers of proviruses. Since this suggested that the differences in phox reconstitution values are caused by variable provirus expression rather than by the number of proviruses per cell, mRNA was purified from the transduced cells and analyzed by Northern blotting using both neo-and gp91-phox-specific probes. Figure 3b shows that all cells expressed the expected full length transcripts initiated at the 5′-LTR and terminating at the 3′-LTR (see Figure 1) . However, no transcripts starting from the internal pgk promoter were detected in MSCVgp91/pgk-neo or MSCVneo/pgk-gp91 transduced cells, probably a reflection of a strong transcriptional interference between the MSCV LTR and the pgk promoter.
Densitometric analysis of the autoradiograms was performed after correction for RNA load. This analysis revealed that the number of full length viral transcripts was slightly higher in MSCVgp91/ires-neo and MSCVneo/pgk-gp91 transduced cells (1.1-to 1.3-fold) MSCVgp91/pgk-neo; 2: MSCVgp91/ires-neo; 3: MSCVneo/pgkgp91; non-transduced X-CGD PLB-985 cells (X-CGD) or wild-type PLB985 (WT) cells were subjected to electrophoresis on a 10% SDS-polyacrylamide gel. Immunoblotting was performed using a cocktail of mouse monoclonal anti gp91-phox antibodies (each at a final dilution of 1:400).
amounts expressed in MSCVgp91/pgk-neo cells. However, there was no correlation between protein levels and the amount of gp91-phox transcripts. While gp91-phox was clearly detectable in MSCVgp91/pgk-neo expressing cells, it was close to background levels in MSCVgp91/ires-neo and MSCVneo/pgk-gp91 transduced cells. Densitometric analysis of immunoblots revealed that MSCVgp91/pgk-neo cells had about 11-25% of wild-type gp91-phox protein levels (Figure 3c) .
Reconstitution of superoxide generating activity was also tested in terminally differentiated phagocytes. For this, mononuclear cells transduced with MSCVgp91/pgk-neo were maintained in suspension cultures with SCF and G-CSF for 3 weeks to stimulate expansion and differentiation of granulocyte progenitors. A 43-fold expansion in total cell numbers was obtained after 3 weeks culture with 40-60% of the cells expressing the granulocytic-specific CD15 anti-gen. The NADPH oxidase activity of the resulting population was estimated by luminol-enhanced chemiluminescence. Mock-transduced cells showed no response above background upon stimulation with PMA, while bone marrow cells from a healthy donor showed a clear NADPH oxidase activity after differentiation and PMA stimulation. MSCVgp91/pgk-neo transduced bone marrow cells showed a clear response to PMA stimulation (Figure 4) . The level of NADPH oxidase activity achieved was 1-2% of that obtained with cells from healthy donors. Furthermore, the kinetics of superoxide production in these cells was slower than that observed for phagocytes derived from normal CD34 + cells.
High reconstitution of respiratory burst activity in phagocytes derived from X-CGD CD34 + bone marrow cells after retroviral-mediated gene transfer
Since the results obtained previously were less than satisfactory, a new retroviral construct (SPsLdS) containing a truncated version of the LNGFR marker gene was constucted. 16 CD34 + cells obtained from the bone marrow of one X-CGD patient were transduced with SPsLdS virus supernate according to the optimized protocol described by Schilz et al. 12 Gene transfer rates in X-CGD bone marrow cells were estimated by FACS analysis from the total number of ⌬LNGFR positive cells at day 5. According to this, the gene transfer rate into X-CGD cells was 79.6%. From these 50.4% co-expressed CD34 and LNGFR (Figure 5a ). After transduction, the cells were kept in suspension cultures in the presence of G-CSF and SCF for 17 days to promote granulocytic differentiation. A 40-50-fold expansion in total cell numbers was obtained at the end of the culture period. At this time, the percentage of cells coexpressing the monocyte/granulocyte specific cell surface marker CD15 and the LNGFR marker was determined by FACS analysis (Figure 5b) . Most of the cells (Ͼ95%) were found to express the CD15 antigen. From these 46.6% were found to co-express the LNGFR+ marker gene (Figure 5b) . A clear response to PMA stimulation was observed in neutrophils derived from transduced CD34 + X-CGD cells. The absolute level of superoxide production achieved in these cells was 68.9% of the control samples (Figure 5c ). In contrast, non-transduced CD15 + X-CGD cells did not show any response to phorbol ester stimulation nor was gp91-phox protein detected in these cells.
Discussion
Through a systematic analysis of retroviral vetor design and gene transfer conditions into CD34 + cells we obtained high and long-lasting expression of the therapeutic gp91-phox gene in phagocytes derived from transduced CD34 + cells. The first series of retroviral constructs were based on the murine stem cell virus (MSCV) because this vector include sequences which have been shown to allow high and longlasting expression in primitive stem cells in vitro and in vivo. [17] [18] [19] The highest reconstitution of NADPH-oxidase activity in X-CGD PLB-985 cells was obtained with MSCVgp91/pgk-neo. The difference in reconstitution efficiency between this construct and the other neomycincontaining vectors could not be attributed to differences in the proviral copy number in the transduced cells, since both cell populations contained roughly equal numbers of integrated viruses. However, no transcripts initiated at the internal pgk promotor were detected in cells transduced with MSCVneo/pgk-gp91, suggesting that the low level of reconstitution achieved with this construct was due to the low expression of gp91-phox. To avoid promoter interference between the viral LTR and the internally located pgk promoter, we decided to construct a bicistronic vector containing an internal ribosome entry site to allow for cap independent translation of the neomycin resistance gene. Transduction of X-CGD PLB-985 cells with MSCV gp91/ires-neo was as efficient as with MSCVgp91/pgk-neo or MSCVneo/pgk-gp91. In this bicistronic construct, selection for the expression of genes positioned downstream of the ires element should result in high levels of expression of the genes located in front of the ires element. In MSCVgp91/ires-neo this was not the case, since superoxide production in cells transduced with this vector was low. The amounts of gp91-phox protein found in extracts of MSCVgp91/ires-neo transduced cells were close to background levels while a clear gp91-phox signal was seen in immunoblots of extracts prepared from MSCVgp91/pgkneo transduced cells.
Phagocytes derived from X-CGD CD34 + cells transduced with MSCVgp91/pgk-neo showed low levels (1-2%) of superoxide producing activity. Most likely only a minor fraction of the CD34 + cells was transduced under the conditions used for these experiments. Since the ultimate goal in the genetic treatment of CGD is the reconstitution of NADPH oxidase activity in the majority of the cells, a series of experiments were performed to find the optimal conditions for transducing CD34 + cells. Our optimized transduction protocol consisted of transductions in serum-free medium in the presence of IL-3, IL-6, SCF, Flt3-L and anti-TGF␤1 antibodies and included a spinoculation step, the use of gibbon ape leukemia virus (GALV) pseudotypes and plates coated with retronectin. 12, 20, 21 Using this protocol for the transduction of X-CGD CD34 + cells and a modified retroviral vector containing a cell surface marker gene (LNGFR), we obtained high levels of gene transfer into CD34
+ cells from X-CGD patients. Moreover superoxide radical production in phagocytes derived from transduced cells was close to 70% of normal values. This is highly relevant for a successful application of somatic gene therapy for CGD, since females carriers of X-CGD with at least 5% to 10% normal neutrophils are protected from acute bacterial infections. 7 Moreover, reconstitution experiments in X-CGD mice transplanted with genetically corrected bone marrow cells have shown that superoxide production levels of about 30% in about 50% of the neutrophils were sufficient to provide protection against an A. fumigatus challenge. 8 Thus, the reconstitution level achieved in this study, may be sufficient to protect CGD patients from life-threatening infections.
In contrast to hematological disorders like adenosine
Bone Marrow Transplantation deaminase deficiency, Fanconi syndrome or severe combined immune deficiency, genetically corrected CGD cells will not have a selective growth advantage over non-transduced cells. Although high levels of gene transfer into stem/progenitor cells may increase the likelihood of engraftment of genetically modified cells, additional strategies will have to be applied in order to ensure high and long lasting engraftment of transduced cells in the patients. Therefore, besides high gene transfer levels, a myeloablative regime or the reinfusion of large quantities of genetically modified cells will be necessary in order to achieve a prolonged clinical benefit for CGD patients.
